Comparison of Sequential to Initial Combination Therapy in PAH
Status:
RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, controlled, double-blind, and non-inferiority clinical trial to compare the efficacy of sequential to initial combination therapy in patients with pulmonary arterial hypertension (PAH). Ambrisentan and Tadalafil will be used in the study. Our research hypothesis is that the efficacy of sequential combination therapy in PAH patients is not inferior to the initial combination therapy as the primary efficacy endpoint is the change in 6MWD at month 12 from baseline.
Phase:
NA
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Affiliated Hospital of Jiaxing University First Affiliated Hospital of Ningbo University First Affiliated Hospital of Wenzhou Medical University Guangdong Provincial People's Hospital Huzhou Central Hospital Ningbo Medical Center Lihuili Hospital Ningbo No.2 Hospital Shanghai Pulmonary Hospital affiliated to Tongji University Taizhou Hospital The Second Affiliated Hospital of Jiaxing University